SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

FATE

FATE THERAPEUTICS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-177171
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the shareholder vote results for the stock plan amendment, which could impact future equity dilution. The other proposals are routine and unlikely to affect operations.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.31
T+0 close · Apr 24, 2026 · via day close
Latest settled
+96.95%
T+60 · $2.58
Vs SPY
+92.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $1.31entry
  2. T+1 · 7mo ago −0.76%α −0.28% · $1.30
  3. T+5 · 7mo ago +37.40%α +37.00% · $1.80
  4. T+20 · 6mo ago +64.12%α +59.17% · $2.15
  5. T+60 · 4mo ago +96.95%α +92.17% · $2.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, proposing the election of three Class I directors, ratification of auditors, advisory approval of executive compensation, and an increase in shares available under its stock option plan.

Key Financial Metrics

Vote
director election
Meeting
2026-06-12
Seats Contested
3

Key Facts

  • Annual shareholder meeting scheduled for June 12, 2026
  • Proposing election of three Class I directors: Robert S. Epstein, Karin Jooss, and Laura J. Hamill
  • Proposing to increase shares available under the 2022 Stock Option and Incentive Plan
  • Proposing ratification of Ernst & Young LLP as independent auditors
  • Proposing non-binding advisory approval of named executive officer compensation

Financial Impact

Potential dilution from increased shares in stock option plan, magnitude undisclosed

dilutionequity compensation

Risk Factors

  • Increased share count from stock plan amendment could lead to shareholder dilution
  • Shareholder opposition to executive compensation could signal governance concerns

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
61% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177171
Document: 0001193125-26-177171-index-headers.html0001193125-26-177171
Document: 0001193125-26-177171-index.html0001193125-26-177171
Document: 0001193125-26-177171.txt0001193125-26-177171

Track record

21 reports on FATE

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  2. Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
  3. Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
  4. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
  5. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  6. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
  7. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  8. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
  9. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
  10. Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026